HUMA — Humacyte, Inc.
—
Nasdaq ·
Health Care ·
Biotechnology ·
CIK 1818382 ·
Last close
$0.50
Market Cap
$139.18M
52W High
$1.52
52W Low
$0.34
ADV30
6,141,273
Next earnings
2026-11-10
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Sep 2026 | — | — | — | — | — | — | — |
| Jun 2026 | 406,000 | -825,000 | -26,996,000 | -36,802,000 | 138,087,000 | 79,903,000 | 106,826,000 |
| Mar 2026 | 495,000 | -1,543,000 | -28,935,000 | -17,619,000 | 110,557,000 | 48,539,000 | 98,933,000 |
| Dec 2025 | 467,000 | -8,615,000 | -30,836,000 | -24,804,000 | 116,366,000 | 50,497,000 | 113,257,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-88,263,000
Investing CF
$-318,000
Financing CF
$133,616,000
CapEx
$-367,000
Dividends Paid
$0
Buybacks
—
EPS Diluted TTM
$-0.42
As of
2026-11-15
Balance + Analyst (yfinance extras)
Retained Earnings
$-796,807,000
Inventory
$5,611,000
Receivables
$811,000
ST Investments
—
EBIT TTM
$-84,708,000
Pretax Income TTM
$-94,763,000
Interest Exp TTM
$10,055,000
Analysts
6
Yahoo Snapshot (yfinance, live)
Total Revenue
$2,396,000
EBITDA
$-102,497,000
Free Cash Flow
$-56,109,624
Enterprise Value
$157,081,456
Total Cash
$64,523,000
Total Debt
$66,482,000
Shares Out
277,798,105
Trailing EPS
$-0.45
Book Value
$0.07
ROE
-1423.6%
ROA
-63.1%
Div Yield
0.00%
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 2,038,000 | -108,137,000 | -40,833,000 | 116,366,000 | 113,257,000 | 3,109,000 | -105,042,000 |
| Dec 2024 | 0 | -114,398,000 | -148,701,000 | 137,872,000 | 190,541,000 | -52,669,000 | -98,122,000 |
| Dec 2023 | 0 | -100,047,000 | -110,776,000 | 128,223,000 | 114,677,000 | 13,546,000 | -73,305,000 |
| Dec 2022 | 0 | -84,578,000 | -11,965,000 | 204,302,000 | 87,374,000 | 116,928,000 | -71,129,000 |
TTM Snapshot
Revenues TTM
$2,121,000
NetIncome TTM
$-96,735,000
OpCashFlow TTM
—
Assets (Latest)
$138,087,000
Forward EPS
$-0.25
Max Pain — expiry 2029-01-19 (volume-derived — Yahoo OI feed degraded)
max pain strike: $1.00 · spot: $0.50 · call volume: 52 · put volume: 280
Expected Move to 2029-01-19:
±$0.65
(130.00%) —
implied range
$-0.15 –
$1.15
· ATM straddle on $0.50 strike
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| TARA | Protara Therapeutics, Inc. | $137.10M | $2.32 | — |
| STRO | SUTRO BIOPHARMA, INC. | $148.08M | $8.92 | — |
| IPHA | Innate Pharma SA | $148.56M | $1.33 | — |
| IVVD | Invivyd, Inc. | $151.09M | $0.51 | — |
| FATE | FATE THERAPEUTICS INC | $124.00M | $1.02 | — |
News headlines (Yahoo Finance, 1h cache)
Humacyte Presents Long-Term Clinical Data Demonstrating Low Atherosclerosis Susceptibility in Acellular Tissue Engineered Vessel
2026-11-16 13:00 · Yahoo
Five Presentations, One Leading Innovation: Humacyte’s Acellular Tissue Engineered Vessel Takes Center Stage at VEITH 2026
2026-11-11 13:00 · Yahoo
Humacyte (HUMA) Q3 2026 Earnings Call Transcript
2026-11-10 22:04 · Yahoo
Humacyte, Inc. Q3 2026 Earnings Call Summary
2026-11-10 21:59 · Yahoo
Humacyte Q3 Earnings Call Highlights
2026-11-10 17:15 · Yahoo
Humacyte, Inc. (HUMA) Reports Q3 Loss, Tops Revenue Estimates
2026-11-10 12:15 · Yahoo
Humacyte Reports Third Quarter 2026 Results, Highlighted by More Than Doubling Symvess Revenue and Expanding Commercial Adoption
2026-11-10 12:00 · Yahoo
Humacyte Highlights First-in-Human Coronary Bypass Study at American Heart Association Scientific Sessions 2026
2026-11-09 13:00 · Yahoo
Humacyte, Inc. (HUMA) Registers a Bigger Fall Than the Market: Important Facts to Note
2026-11-05 22:00 · Yahoo
Humacyte Innovative Research in Coronary Bypass and Vascular Regeneration to be Highlighted at American Heart Association Scientific Sessions 2026
2026-11-03 13:00 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.